LT5701B - Phytochemical composition, method of preparation and use thereof - Google Patents
Phytochemical composition, method of preparation and use thereof Download PDFInfo
- Publication number
- LT5701B LT5701B LT2010027A LT2010027A LT5701B LT 5701 B LT5701 B LT 5701B LT 2010027 A LT2010027 A LT 2010027A LT 2010027 A LT2010027 A LT 2010027A LT 5701 B LT5701 B LT 5701B
- Authority
- LT
- Lithuania
- Prior art keywords
- composition
- carum carvi
- essential oils
- ethyl alcohol
- fruit
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 31
- 229930000223 plant secondary metabolite Natural products 0.000 title claims description 13
- 235000017807 phytochemicals Nutrition 0.000 title claims description 9
- 238000002360 preparation method Methods 0.000 title abstract description 12
- 238000000034 method Methods 0.000 title description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 40
- 240000000467 Carum carvi Species 0.000 claims abstract description 39
- 235000005747 Carum carvi Nutrition 0.000 claims abstract description 34
- 239000000341 volatile oil Substances 0.000 claims abstract description 19
- 208000030270 breast disease Diseases 0.000 claims abstract description 15
- ULDHMXUKGWMISQ-UHFFFAOYSA-N carvone Chemical compound CC(=C)C1CC=C(C)C(=O)C1 ULDHMXUKGWMISQ-UHFFFAOYSA-N 0.000 claims abstract description 12
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000002904 solvent Substances 0.000 claims abstract description 6
- 239000005973 Carvone Substances 0.000 claims abstract description 5
- 229930003935 flavonoid Natural products 0.000 claims abstract description 5
- 150000002215 flavonoids Chemical class 0.000 claims abstract description 5
- 235000017173 flavonoids Nutrition 0.000 claims abstract description 5
- 235000001510 limonene Nutrition 0.000 claims abstract description 5
- 229940087305 limonene Drugs 0.000 claims abstract description 5
- 150000003431 steroids Chemical class 0.000 claims abstract description 4
- 235000007129 Cuminum cyminum Nutrition 0.000 claims description 20
- 235000019441 ethanol Nutrition 0.000 claims description 18
- 235000013399 edible fruits Nutrition 0.000 claims description 16
- 229940098465 tincture Drugs 0.000 claims description 11
- 238000011282 treatment Methods 0.000 claims description 10
- 229930006000 Sucrose Natural products 0.000 claims description 7
- 239000005720 sucrose Substances 0.000 claims description 7
- 244000304337 Cuminum cyminum Species 0.000 claims description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 6
- 238000011287 therapeutic dose Methods 0.000 claims description 4
- 235000012054 meals Nutrition 0.000 claims description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 2
- 239000011707 mineral Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000000185 sucrose group Chemical group 0.000 claims 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 abstract description 11
- 230000001225 therapeutic effect Effects 0.000 abstract description 7
- 230000036541 health Effects 0.000 abstract description 2
- 208000000571 Fibrocystic breast disease Diseases 0.000 abstract 1
- 208000011803 breast fibrocystic disease Diseases 0.000 abstract 1
- 239000000284 extract Substances 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 19
- 241000196324 Embryophyta Species 0.000 description 15
- 241000510672 Cuminum Species 0.000 description 14
- 230000000694 effects Effects 0.000 description 10
- 239000003814 drug Substances 0.000 description 8
- -1 Thymus zugis Substances 0.000 description 7
- 230000002062 proliferating effect Effects 0.000 description 7
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 7
- KRCZYMFUWVJCLI-UHFFFAOYSA-N Dihydrocarveol Chemical compound CC1CCC(C(C)=C)CC1O KRCZYMFUWVJCLI-UHFFFAOYSA-N 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 210000005075 mammary gland Anatomy 0.000 description 5
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- REFJWTPEDVJJIY-UHFFFAOYSA-N quercetin Natural products C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- BAVONGHXFVOKBV-UHFFFAOYSA-N Carveol Chemical compound CC(=C)C1CC=C(C)C(O)C1 BAVONGHXFVOKBV-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 240000004760 Pimpinella anisum Species 0.000 description 4
- 208000009956 adenocarcinoma Diseases 0.000 description 4
- 230000001093 anti-cancer Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 3
- 240000006927 Foeniculum vulgare Species 0.000 description 3
- 208000018522 Gastrointestinal disease Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 235000012550 Pimpinella anisum Nutrition 0.000 description 3
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 206010016766 flatulence Diseases 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 3
- CNVZJPUDSLNTQU-SEYXRHQNSA-N petroselinic acid Chemical compound CCCCCCCCCCC\C=C/CCCCC(O)=O CNVZJPUDSLNTQU-SEYXRHQNSA-N 0.000 description 3
- 235000005875 quercetin Nutrition 0.000 description 3
- 229960001285 quercetin Drugs 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- BAVONGHXFVOKBV-NXEZZACHSA-N (-)-cis-carveol Chemical compound CC(=C)[C@@H]1CC=C(C)[C@H](O)C1 BAVONGHXFVOKBV-NXEZZACHSA-N 0.000 description 2
- BAVONGHXFVOKBV-ZJUUUORDSA-N (-)-trans-carveol Natural products CC(=C)[C@@H]1CC=C(C)[C@@H](O)C1 BAVONGHXFVOKBV-ZJUUUORDSA-N 0.000 description 2
- GRWFGVWFFZKLTI-IUCAKERBSA-N (-)-α-pinene Chemical compound CC1=CC[C@@H]2C(C)(C)[C@H]1C2 GRWFGVWFFZKLTI-IUCAKERBSA-N 0.000 description 2
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 2
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 2
- 241000208173 Apiaceae Species 0.000 description 2
- 239000002028 Biomass Substances 0.000 description 2
- 244000018436 Coriandrum sativum Species 0.000 description 2
- 235000002787 Coriandrum sativum Nutrition 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 235000004204 Foeniculum vulgare Nutrition 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- KRCZYMFUWVJCLI-BBBLOLIVSA-N Neodihydrocarveol Natural products C[C@@H]1CC[C@@H](C(C)=C)C[C@@H]1O KRCZYMFUWVJCLI-BBBLOLIVSA-N 0.000 description 2
- 240000007164 Salvia officinalis Species 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- MOYAFQVGZZPNRA-UHFFFAOYSA-N Terpinolene Chemical compound CC(C)=C1CCC(C)=CC1 MOYAFQVGZZPNRA-UHFFFAOYSA-N 0.000 description 2
- 244000273928 Zingiber officinale Species 0.000 description 2
- 235000006886 Zingiber officinale Nutrition 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000012675 alcoholic extract Substances 0.000 description 2
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 235000001671 coumarin Nutrition 0.000 description 2
- 125000000332 coumarinyl group Chemical class O1C(=O)C(=CC2=CC=CC=C12)* 0.000 description 2
- 239000001598 cuminum cyminum l. fruit extract Substances 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 229930007024 dihydrocarveol Natural products 0.000 description 2
- AZOCECCLWFDTAP-RKDXNWHRSA-N dihydrocarvone Natural products C[C@@H]1CC[C@@H](C(C)=C)CC1=O AZOCECCLWFDTAP-RKDXNWHRSA-N 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N flavone Chemical compound O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 235000008397 ginger Nutrition 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229930007744 linalool Natural products 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 230000002438 mitochondrial effect Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- NDVASEGYNIMXJL-UHFFFAOYSA-N sabinene Chemical compound C=C1CCC2(C(C)C)C1C2 NDVASEGYNIMXJL-UHFFFAOYSA-N 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 2
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- NPNUFJAVOOONJE-ZIAGYGMSSA-N β-(E)-Caryophyllene Chemical compound C1CC(C)=CCCC(=C)[C@H]2CC(C)(C)[C@@H]21 NPNUFJAVOOONJE-ZIAGYGMSSA-N 0.000 description 2
- USDOQCCMRDNVAH-KKUMJFAQSA-N β-cadinene Chemical compound C1C=C(C)C[C@H]2[C@H](C(C)C)CC=C(C)[C@@H]21 USDOQCCMRDNVAH-KKUMJFAQSA-N 0.000 description 2
- YKFLAYDHMOASIY-UHFFFAOYSA-N γ-terpinene Chemical compound CC(C)C1=CCC(C)=CC1 YKFLAYDHMOASIY-UHFFFAOYSA-N 0.000 description 2
- NDVASEGYNIMXJL-NXEZZACHSA-N (+)-sabinene Natural products C=C1CC[C@@]2(C(C)C)[C@@H]1C2 NDVASEGYNIMXJL-NXEZZACHSA-N 0.000 description 1
- WTARULDDTDQWMU-RKDXNWHRSA-N (+)-β-pinene Chemical compound C1[C@H]2C(C)(C)[C@@H]1CCC2=C WTARULDDTDQWMU-RKDXNWHRSA-N 0.000 description 1
- WTARULDDTDQWMU-IUCAKERBSA-N (-)-Nopinene Natural products C1[C@@H]2C(C)(C)[C@H]1CCC2=C WTARULDDTDQWMU-IUCAKERBSA-N 0.000 description 1
- MGRKVRJGCZXQGW-NPPUSCPJSA-N (1s,5s)-4,7,7-trimethyl-6-oxabicyclo[3.2.1]octane Chemical compound CC1CC[C@@H]2C(C)(C)O[C@H]1C2 MGRKVRJGCZXQGW-NPPUSCPJSA-N 0.000 description 1
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- DIIIISSCIXVANO-UHFFFAOYSA-N 1,2-Dimethylhydrazine Chemical compound CNNC DIIIISSCIXVANO-UHFFFAOYSA-N 0.000 description 1
- PFKYCGAUNWCWNO-UHFFFAOYSA-N 1,5-diphenyl-1h-tetrazol-1-ium;bromide Chemical compound [Br-].C1=CC=CC=C1[NH+]1C(C=2C=CC=CC=2)=NN=N1 PFKYCGAUNWCWNO-UHFFFAOYSA-N 0.000 description 1
- OXEDXHIBHVMDST-UHFFFAOYSA-N 12Z-octadecenoic acid Natural products CCCCCC=CCCCCCCCCCCC(O)=O OXEDXHIBHVMDST-UHFFFAOYSA-N 0.000 description 1
- NJZUUYADLXBQPA-UHFFFAOYSA-N 2,2-Dimethyl-5-methylen-norbornan Natural products C1C2C(C)(C)CC1C(=C)C2 NJZUUYADLXBQPA-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- AZOCECCLWFDTAP-UHFFFAOYSA-N 2-methyl-5-(1-methylethenyl)cyclohexanone Natural products CC1CCC(C(C)=C)CC1=O AZOCECCLWFDTAP-UHFFFAOYSA-N 0.000 description 1
- WRYLYDPHFGVWKC-UHFFFAOYSA-N 4-terpineol Chemical compound CC(C)C1(O)CCC(C)=CC1 WRYLYDPHFGVWKC-UHFFFAOYSA-N 0.000 description 1
- ZGMLACURZVGTPK-UHFFFAOYSA-N 5-fluoranyl-1h-pyrimidine-2,4-dione Chemical compound OC1=NC=C(F)C(O)=N1.FC1=CNC(=O)NC1=O ZGMLACURZVGTPK-UHFFFAOYSA-N 0.000 description 1
- QEVHRUUCFGRFIF-UHFFFAOYSA-N 6,18-dimethoxy-17-[oxo-(3,4,5-trimethoxyphenyl)methoxy]-1,3,11,12,14,15,16,17,18,19,20,21-dodecahydroyohimban-19-carboxylic acid methyl ester Chemical compound C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-UHFFFAOYSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- 241000722941 Achillea Species 0.000 description 1
- 241001061264 Astragalus Species 0.000 description 1
- 235000009109 Betula pendula Nutrition 0.000 description 1
- 241000219430 Betula pendula Species 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000219198 Brassica Species 0.000 description 1
- 235000011331 Brassica Nutrition 0.000 description 1
- 240000007124 Brassica oleracea Species 0.000 description 1
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 1
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 1
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000202726 Bupleurum Species 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- UGTJLJZQQFGTJD-UHFFFAOYSA-N Carbonylcyanide-3-chlorophenylhydrazone Chemical compound ClC1=CC=CC(NN=C(C#N)C#N)=C1 UGTJLJZQQFGTJD-UHFFFAOYSA-N 0.000 description 1
- WLYGSPLCNKYESI-RSUQVHIMSA-N Carthamin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1[C@@]1(O)C(O)=C(C(=O)\C=C\C=2C=CC(O)=CC=2)C(=O)C(\C=C\2C([C@](O)([C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C(O)=C(C(=O)\C=C\C=3C=CC(O)=CC=3)C/2=O)=O)=C1O WLYGSPLCNKYESI-RSUQVHIMSA-N 0.000 description 1
- 241000208809 Carthamus Species 0.000 description 1
- 241001310324 Cetraria islandica Species 0.000 description 1
- 244000103926 Chamaenerion angustifolium Species 0.000 description 1
- 235000006890 Chamerion angustifolium subsp angustifolium Nutrition 0.000 description 1
- 206010008617 Cholecystitis chronic Diseases 0.000 description 1
- 241000723347 Cinnamomum Species 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 241000218176 Corydalis Species 0.000 description 1
- 241000234653 Cyperus Species 0.000 description 1
- 108020005199 Dehydrogenases Proteins 0.000 description 1
- 208000007163 Dermatomycoses Diseases 0.000 description 1
- 241000792890 Diervilla Species 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010015958 Eye pain Diseases 0.000 description 1
- 241000555712 Forsythia Species 0.000 description 1
- 241000605372 Fritillaria Species 0.000 description 1
- 240000002045 Guettarda speciosa Species 0.000 description 1
- 235000001287 Guettarda speciosa Nutrition 0.000 description 1
- 241000257303 Hymenoptera Species 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 241001562081 Ikeda Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 241000207840 Jasminum Species 0.000 description 1
- 240000008415 Lactuca sativa Species 0.000 description 1
- 240000007890 Leonurus cardiaca Species 0.000 description 1
- 235000017143 Leonurus cardiaca Nutrition 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 244000042664 Matricaria chamomilla Species 0.000 description 1
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 1
- 241000213996 Melilotus Species 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 241001479543 Mentha x piperita Species 0.000 description 1
- 240000000987 Monstera deliciosa Species 0.000 description 1
- 241000742170 Mosia Species 0.000 description 1
- 241000124738 Myrrhis Species 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 240000007926 Ocimum gratissimum Species 0.000 description 1
- 235000004066 Ocimum gratissimum Nutrition 0.000 description 1
- 241001529744 Origanum Species 0.000 description 1
- 235000010677 Origanum vulgare Nutrition 0.000 description 1
- 240000007673 Origanum vulgare Species 0.000 description 1
- 241000736199 Paeonia Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- CNVZJPUDSLNTQU-UHFFFAOYSA-N Petroselaidic acid Natural products CCCCCCCCCCCC=CCCCCC(O)=O CNVZJPUDSLNTQU-UHFFFAOYSA-N 0.000 description 1
- 235000018976 Philodendron bipinnatifidum Nutrition 0.000 description 1
- 241000722363 Piper Species 0.000 description 1
- 235000008184 Piper nigrum Nutrition 0.000 description 1
- 244000203593 Piper nigrum Species 0.000 description 1
- 241000543704 Pistacia Species 0.000 description 1
- 235000003445 Pistacia Nutrition 0.000 description 1
- 241000756042 Polygonatum Species 0.000 description 1
- 241000205407 Polygonum Species 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 244000179560 Prunella vulgaris Species 0.000 description 1
- 241000220299 Prunus Species 0.000 description 1
- 235000011432 Prunus Nutrition 0.000 description 1
- 244000078856 Prunus padus Species 0.000 description 1
- WTARULDDTDQWMU-UHFFFAOYSA-N Pseudopinene Natural products C1C2C(C)(C)C1CCC2=C WTARULDDTDQWMU-UHFFFAOYSA-N 0.000 description 1
- 244000233562 Psidium araca Species 0.000 description 1
- 235000012087 Psidium araca Nutrition 0.000 description 1
- 244000184734 Pyrus japonica Species 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 235000017276 Salvia Nutrition 0.000 description 1
- 235000002912 Salvia officinalis Nutrition 0.000 description 1
- 241001530126 Scrophularia Species 0.000 description 1
- 241000207929 Scutellaria Species 0.000 description 1
- 240000000452 Sesamum alatum Species 0.000 description 1
- 235000009367 Sesamum alatum Nutrition 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 241000521126 Silphium Species 0.000 description 1
- NLDBCFRIELDMRO-UHFFFAOYSA-N Stigmasterin Natural products CCCC(CC)C=CC(C)C1CCC2C3CC=C4CC(O)CCC4(C)C3CCC12C NLDBCFRIELDMRO-UHFFFAOYSA-N 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- 240000002657 Thymus vulgaris Species 0.000 description 1
- 235000007303 Thymus vulgaris Nutrition 0.000 description 1
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 241001247821 Ziziphus Species 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- XCPQUQHBVVXMRQ-UHFFFAOYSA-N alpha-Fenchene Natural products C1CC2C(=C)CC1C2(C)C XCPQUQHBVVXMRQ-UHFFFAOYSA-N 0.000 description 1
- QMAYBMKBYCGXDH-UHFFFAOYSA-N alpha-amorphene Natural products C1CC(C)=CC2C(C(C)C)CC=C(C)C21 QMAYBMKBYCGXDH-UHFFFAOYSA-N 0.000 description 1
- MVNCAPSFBDBCGF-UHFFFAOYSA-N alpha-pinene Natural products CC1=CCC23C1CC2C3(C)C MVNCAPSFBDBCGF-UHFFFAOYSA-N 0.000 description 1
- KQAZVFVOEIRWHN-UHFFFAOYSA-N alpha-thujene Natural products CC1=CCC2(C(C)C)C1C2 KQAZVFVOEIRWHN-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002365 anti-tubercular Effects 0.000 description 1
- 230000000026 anti-ulcerogenic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- HINAOCRDJFBYGD-UHFFFAOYSA-N beta-Fenchen Natural products C1CC2C(C)(C)CC1(C)C2 HINAOCRDJFBYGD-UHFFFAOYSA-N 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- NPNUFJAVOOONJE-UHFFFAOYSA-N beta-cariophyllene Natural products C1CC(C)=CCCC(=C)C2CC(C)(C)C21 NPNUFJAVOOONJE-UHFFFAOYSA-N 0.000 description 1
- UAHWPYUMFXYFJY-UHFFFAOYSA-N beta-myrcene Natural products CC(C)=CCCC(=C)C=C UAHWPYUMFXYFJY-UHFFFAOYSA-N 0.000 description 1
- 229930006722 beta-pinene Natural products 0.000 description 1
- 235000013614 black pepper Nutrition 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 238000007816 calorimetric assay Methods 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000001862 carum carvi l. seed oil Substances 0.000 description 1
- RECUKUPTGUEGMW-UHFFFAOYSA-N carvacrol Chemical compound CC(C)C1=CC=C(C)C(O)=C1 RECUKUPTGUEGMW-UHFFFAOYSA-N 0.000 description 1
- HHTWOMMSBMNRKP-UHFFFAOYSA-N carvacrol Natural products CC(=C)C1=CC=C(C)C(O)=C1 HHTWOMMSBMNRKP-UHFFFAOYSA-N 0.000 description 1
- 235000007746 carvacrol Nutrition 0.000 description 1
- 229930007646 carveol Natural products 0.000 description 1
- WPGPCDVQHXOMQP-UHFFFAOYSA-N carvotanacetone Natural products CC(C)C1CC=C(C)C(=O)C1 WPGPCDVQHXOMQP-UHFFFAOYSA-N 0.000 description 1
- NPNUFJAVOOONJE-UONOGXRCSA-N caryophyllene Natural products C1CC(C)=CCCC(=C)[C@@H]2CC(C)(C)[C@@H]21 NPNUFJAVOOONJE-UONOGXRCSA-N 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 210000001968 dental pulp cell Anatomy 0.000 description 1
- 201000003929 dermatomycosis Diseases 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 229940124600 folk medicine Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 229940068517 fruit extracts Drugs 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- LCWMKIHBLJLORW-UHFFFAOYSA-N gamma-carene Natural products C1CC(=C)CC2C(C)(C)C21 LCWMKIHBLJLORW-UHFFFAOYSA-N 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- WYXXLXHHWYNKJF-UHFFFAOYSA-N isocarvacrol Natural products CC(C)C1=CC=C(O)C(C)=C1 WYXXLXHHWYNKJF-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 1
- 230000001983 lactogenic effect Effects 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 238000002647 laser therapy Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 239000001771 mentha piperita Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229930003658 monoterpene Natural products 0.000 description 1
- 235000002577 monoterpenes Nutrition 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 235000019520 non-alcoholic beverage Nutrition 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000001909 pimpinella anisum Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- GRWFGVWFFZKLTI-UHFFFAOYSA-N rac-alpha-Pinene Natural products CC1=CCC2C(C)(C)C1C2 GRWFGVWFFZKLTI-UHFFFAOYSA-N 0.000 description 1
- 229910052704 radon Inorganic materials 0.000 description 1
- SYUHGPGVQRZVTB-UHFFFAOYSA-N radon atom Chemical compound [Rn] SYUHGPGVQRZVTB-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001373 regressive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 229930006696 sabinene Natural products 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 235000012045 salad Nutrition 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- USDOQCCMRDNVAH-UHFFFAOYSA-N sigma-cadinene Natural products C1C=C(C)CC2C(C(C)C)CC=C(C)C21 USDOQCCMRDNVAH-UHFFFAOYSA-N 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 235000016831 stigmasterol Nutrition 0.000 description 1
- 229940032091 stigmasterol Drugs 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 210000004233 talus Anatomy 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- 239000001585 thymus vulgaris Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- GCRTVIUGJCJVDD-IUCAKERBSA-N trans-Dihydrocarvone Chemical compound CC(C)[C@H]1CC[C@H](C)C(=O)C1 GCRTVIUGJCJVDD-IUCAKERBSA-N 0.000 description 1
- AQWHMKSIVLSRNY-UHFFFAOYSA-N trans-Octadec-5-ensaeure Natural products CCCCCCCCCCCCC=CCCCC(O)=O AQWHMKSIVLSRNY-UHFFFAOYSA-N 0.000 description 1
- RUVINXPYWBROJD-ONEGZZNKSA-N trans-anethole Chemical compound COC1=CC=C(\C=C\C)C=C1 RUVINXPYWBROJD-ONEGZZNKSA-N 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- RRBYUSWBLVXTQN-UHFFFAOYSA-N tricyclene Chemical compound C12CC3CC2C1(C)C3(C)C RRBYUSWBLVXTQN-UHFFFAOYSA-N 0.000 description 1
- RRBYUSWBLVXTQN-VZCHMASFSA-N tricyclene Natural products C([C@@H]12)C3C[C@H]1C2(C)C3(C)C RRBYUSWBLVXTQN-VZCHMASFSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000001841 zingiber officinale Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Išradimas priklauso sveikatos apsaugos sričiai, būtent vaistiniams preparatams, savo sudėtyje turintiems organinių veikliųjų ingredientų. Jis pagrįstas fitocheminių junginių, kaip terapinio preparato, gavimu ir panaudojimu gydant cistinę fibrozinę krūties ligų- mastopatiją.The present invention relates to the field of health care, in particular to pharmaceutical preparations containing organic active ingredients. It is based on the preparation and use of phytochemical compounds as a therapeutic agent in the treatment of cystic fibrotic breast disease - mastopathy.
Mastopatijos patogenezę sudaro nuo fiziologinės normos nukryps.tantys būties audinio pokyčiai. Šie pokyčiai yra proliferacinio (vešėjimo) ir neproliferacinio (regresinio) pobūdžio. Liga prasideda difuzine ir progresuoja į mazginę (židininę) formų. Supiktybėti gali visiį rūšių proliferacinė ir kai kurių rūšių neproliferacinė mastopatija. Įvairių formų mastopatija serga iki 45 % (ypač vyresnio amžiaus) moterų.The pathogenesis of mastopathy consists of abnormal changes in the tissue of physiology. These changes are of a proliferative (non-proliferative) and non-proliferative (regressive) nature. The disease begins with diffuse and progresses to nodular (focal) forms. All types of proliferative and some types of non-proliferative mastopathy can be confused. Various forms of mastopathy affect up to 45% of women (especially the elderly).
Mastopatijai gydyti (proliferacinė operuojama) vis labiau naudojami nespecifiniai fitoterapiniai preparatai. Pastaruoju metu (XXI a. pirmajame dešimtmetyje) fitocheminių junginių paieškomis ypač aktyviai užsiima kinų specialistai. Jie naudojasi per ilgą laiką sukaupta kinų tradicinės medicinos patirtimi ir sudaro įvairias vaistinių augalų kompozicijas mastopatijai gydyti. Žinomos 4-6 vaistinių augalų kompozicijos [patentai: CN 101129527 (A), CN 1657069 (A), CN 1757297 (A), CN 1895441 (A)]. Į šių kompozicijų sudėtį įeina Bupleurum, Jasminum, Reynotria, Polygonatum, Ziziphus, Carthamus genčių vaistiniai augalai. Taip pat žinomos 7-10 vaistinių augalų kompozicijos [patentai CN 101214298 (A); CN 1861183 (A); CN 1493349 (A); CN 1726989 (A); CN 1385202 (A); CN 1883552 (A); CN 101361805 (A); CN 101224249 (A); CN 100998845 (A)]. Šiose kompozicijose vyrauja tokie vietinių vaistinių augalų genčių augalai: Angelica, Amygdalus, Scrophularia, Forsythia, Cinnamomum, Pistacia, Myrrhis, Cyperus, Paeonia, Diervilla, Salvia, Philodendron, Rheum, Silphium, Scutellaria, Sesamum, Xeranthemum augalai. Pastaraisiais metais Kinijoje patentuotos 24-35 vaistinių augalų rūšių kompozicijos įvairiems mastopatijos tipams gydyti [patentai: CN 101485862 (A), 2009-07-22 (A); CN 1695694 (A); CN 1759899 (A)]. Šiose kompozicijose be jau paminėtų augalų randame Polygonum, Astragalus, Ραηαχ, Corydalis, Fritillaria, Prunella, Brassica ir kitų genčių vaistinius augalus.Non-specific phytotherapeutic agents are increasingly used to treat mastopathy (proliferative surgery). Recently (in the first decade of the 21st century), Chinese specialists have been particularly active in the search for phytochemical compounds. They draw on the long-standing experience of Chinese traditional medicine and form various herbal compositions for mastopathy. Compositions of 4-6 medicinal plants are known [patents: CN 101129527 (A), CN 1657069 (A), CN 1757297 (A), CN 1895441 (A)]. These compositions include medicinal plants of the genera Bupleurum, Jasminum, Reynotria, Polygonatum, Ziziphus, Carthamus. Also known are compositions of 7-10 medicinal plants [patents CN 101214298 (A); CN 1861183 (A); CN 1493349 (A); CN 1726989 (A); CN 1385202 (A); CN 1883552 (A); CN 101361805 (A); CN 101224249 (A); CN 100998845 (A)]. The following native medicinal herbaceous plants are predominant in these compositions: Angelica, Amygdalus, Scrophularia, Forsythia, Cinnamomum, Pistacia, Myrrhis, Cyperus, Paeonia, Diervilla, Salvia, Philodendron, Rheum, Silphium, Scutellaria, Sesamum, Xeranth. In recent years, compositions of 24-35 medicinal plant species have been patented in China for the treatment of various types of mastopathy [patents: CN 101485862 (A), 2009-07-22 (A); CN 1695694 (A); CN 1759899 (A)]. In these compositions, besides the plants already mentioned, we find medicinal plants of Polygonum, Astragalus, Ραηαχ, Corydalis, Fritillaria, Prunella, Brassica and other genera.
Sukurtos kompozicijos pasižymi mastopatiją inhibuojančiomis savybėmis, tačiau jų trūkumas yra tas, kad šis inhibavimas yra vertinamas tik patenkinamai (vidutinis inhibavimo lygis).The formulations developed exhibit mastopathic inhibitory properties, but their disadvantage is that this inhibition is rated only satisfactorily (average level of inhibition).
Mastopatįjai gydyti vartojamos ir vidutinio klimato zonos vaistinių augalų kompozicijos (RU patentas 2 066 168 Cl). Šią kompoziciją sudaro Matricaria recutita, Melilotus officinale, Leonurus cardiaca, Padus avium, Epilobium angustifolium, Achillea. millefolium, Origanum vulgare, Betula pendula (pumpurai). Šios paskirties preparatui gauti taip pat naudojamos kerpės Cetraria islandica (RU patentas 2034561 Cl). Žinomas gydymo būdas, kai naudojamos (RU patentas 2 234 958 C2) radono procedūros (vonia) su kintančių bangų lazerio terapija (veikiant pieno liaukas), o taip pat milimetrinio diapazono elektromagnetinės bangos, veikiant jomis biologiškai aktyvius VC-17 ir RP-6 taškus (RU patentas 2 257 921 C2). Šiomis priemonėmis padidinamas nespecifinis organizmo atsparumas bei patogenezė, tačiau šis poveikis yra ribotas.Medico-climatic herbal compositions for treating mastopathies (RU patent 2,066,168 Cl). This composition includes Matricaria recutita, Melilotus officinale, Leonurus cardiaca, Padus avium, Epilobium angustifolium, Achillea. millefolium, Origanum vulgare, Betula pendula (bud). Lichens Cetraria islandica (RU patent 2034561 Cl) are also used for this preparation. Known treatment using (RU patent 2 234 958 C2) radon procedures (bath) with alternating-wave laser therapy (acting on the mammary glands) as well as millimeter-range electromagnetic waves acting on biologically active points VC-17 and RP-6 (RU Patent 2,257,921 C2). These measures increase non-specific resistance and pathogenesis in the body, but these effects are limited.
Taip pat žinomas Indijos Mokslinio ir taikomojo tyrimo tarybos (Council of scientific and industrial research) specialistų grupės (sudaryta iš 12 tyrėjų) ištirtas vaistinių augalų Carum carvi (paprastasis kmynas), Zingiber officinale (imbieras tikrasis), Cuminum cyminum (kmyninis kuminas) ir Piper nigrum (juodasis pipiras) kompozicijos ekstrakto sinergetinis poveikis įvairiems gydomiesiems preparatams, padidinantis jų veikimo efektyvumą (WO 2004/067018 Al). Į šių preparatų sąrašą buvo įtraukti onkologijos praktikoje naudojami metotreksatas (methotrexate) ir 5-fluoruracilas (5-fluorouracil).Also known is the Carum carvi, Zingiber officinale (ginger true), Cuminum cyminum (caraway cumin) and Piper (herb carum carvi), a group of 12 researchers from the Indian Council of Scientific and Industrial Research. nigrum (black pepper) composition extract synergistic effect on various therapeutic preparations, increasing their effectiveness (WO 2004/067018 Al). Those products included methotrexate (methotrexate) and 5-fluorouracil (5-fluorouracil) used in oncology practice.
Šio sprendimo trūkumas yra tas, kad kompozicija tik pagerina cheminių gydomųjų preparatų veikimą.The disadvantage of this solution is that the composition only improves the performance of chemical therapeutic agents.
Artimiausia siūlomam techniniam sprendimui yra farmacinė kompozicija, kuriai gaminti panaudojami aromatinių augalų eteriniai aliejai (WO 9 637 210 (A2) patentas). Kompoziciją sudaro Origanum vulgaris, Thymus vulgaris, Thymus zugis, Mentha piperita, Thymus serpilum, Saturea hortensis, Saturea montana, Saturea subricata, Carum corticum, Ocimum gratissimum, Moranda punctata, Mosią japonica ir Salvia officinalis augalų eteriniai aliejai. Kompozicija naudojama kolibaciliozės, dermatomikozės, , burnos gleivinės uždegimo, pūliuojančių žaizdų gydymui ir kt. atvejais.Closest to the proposed technical solution is a pharmaceutical composition which utilizes aromatic plant essential oils (WO 9 637 210 (A2) patent). The composition comprises essential oils of the plants Origanum vulgaris, Thymus vulgaris, Thymus zugis, Mentha piperita, Thymus serpilum, Saturea hortensis, Saturea montana, Saturea subricata, Carum corticum, Ocimum gratissimum, Moranda punctata, Mosia japonica and Salvia officinalis. The composition is used for the treatment of colibacillosis, dermatomycosis, inflammation of the oral mucosa, purulent wounds and others. cases.
Šio sprendimo trūkumas yra tas, kad palyginti sudėtingos vaistinių augalų kompozicijos ekstraktas pasižymi siauru veikimo spektru, nerodo biologinio aktyvumo gydant mastopatiją.The disadvantage of this solution is that the relatively complex medicinal plant composition extract has a narrow spectrum of action and does not show biological activity in mastopathy treatment.
Siūlomo išradimo užduotis - sukurti preparatą - fitocheminių junginių derinį, kuris užtikrintų preparato biologinį aktyvumą gydant mastopatiją, būtų stabilus, pasižymėtų teigiamu veikimu žmogaus organizmui, būtų pranašesnis, palyginti su kitais žinomais analogiškais preparatais bei gydymo priemonėmis ir kurio gamyba būtų nesudėtinga bei preparatas būtų nebrangus.The object of the present invention is to provide a preparation - a combination of phytochemical compounds, which ensures the biological activity of the preparation in the treatment of mastopathy, is stable, has a positive effect on the human body, compares favorably with other known analogous preparations and therapies.
Užduotis išsprendžiama fitocheminių junginių kompozicija, apimančia eterinius aliejus ir tirpiklį, kurioje eterinius aliejus sudaro fitocheminių junginių karvono, limoneno, steroidų, flavonoidų, esančių vaistinio augalo Carum carvi (kmyno) vaisiuose kompleksas, o tirpiklis yra 60-96 % etilo alkoholis, kur kompozicijos komponentai įeina tokiu masės dalių santykiu: Carum carvi vaisiai ir 60-96 % etilo alkoholis maždaug 1:5.The object is solved by a composition of phytochemicals comprising essential oils and a solvent comprising a complex of phytochemicals of carvone, limonene, steroids, flavonoids in the fruit of the medicinal plant Carum carvi (cumin), the solvent being 60-96% ethyl alcohol, comes in the following weight ratio: Carum carvi fruit and 60-96% ethyl alcohol in about 1: 5.
Kompozicija apima visą fitocheminių gydomųjų junginių kompleksą. Jį sudaro 5-7 % eterinio aliejaus, kuriame randame teipeno darinių: 50-60 % karvono, 30-40 % limoneno ir mažesniais kiekiais - dihidrokarvono, dihidrokarveolio, karveolio, linaloolio; komplekso sudėtyje taip pat yra flavonoidų - kvercetino ir kamferolio, taninų, dervingų medžiagų, baltymų, riebalų rūgščių. Šios farmakologiniu požiūriu aktyvios gydomosios medžiagos telkiasi vaistinio augalo Carum carvi (paprastojo kmyno) vaisiuose.The composition comprises the entire complex of phytochemical therapeutic compounds. It contains 5-7% of the essential oil in which we find teipene derivatives: 50-60% carvone, 30-40% limonene and in smaller amounts - dihydrocarvone, dihydrocarveol, carveol, linalool; the complex also contains flavonoids - quercetin and camphorol, tannins, resins, proteins, fatty acids. These pharmacologically active therapeutic substances are concentrated in the fruits of the medicinal plant Carum carvi.
Carum carvi (paprastasis kmynas) yra dvimetis arba daugiametis žolinis augalas. Jo aukštis 50-100 cm. Stiebas status, šakotas. Žiedynas - sudėtinis skėtis. Žiedai maži, balti arba kiek rausvi. Žydi vidutinio klimato juostoje gegužės-birželio mėn. Vaisiai subręsta birželio-liepos mėn. Jie 3-7 mm ilgio ir 1,0-1,5 mm pločio. Paplitęs Europoje ir Azijoje. Kultivuojamas.Carum carvi (caraway) is a biennial or perennial herbaceous plant. Its height is 50-100 cm. Stem status, branched. Inflorescence - composite umbrella. The rings are small, white or slightly pink. Blooms in temperate climate zone May-June. The fruits ripen in June-July. They are 3-7 mm long and 1.0-1.5 mm wide. Common in Europe and Asia. Cultivated.
Augalo vaisiai naudojami maisto ir konditerijos pramonėje, parfumerijoje. Buityje - rauginant kopūstus, sūrių gamyboje, kepant duoną, kulinarijoje (KomeeB A. K., JĮnKopacTymue CT»eao6HMe pacTeHHH b HameM πητβηηη, M., 1980, 256 c.; Food technol. Abstr., 1974, N 93, p. 470) Jų dedama į giras ir kitus nealkoholinius ir alkoholinius gėrimus. Jauni lapai tinka salotoms, sriuboms. Iš žiedų bitės prineša per 100 kg/ha nektaro.The fruits of the plant are used in the food and confectionery industry, in perfumery. Domestic - fermenting cabbage, cheese making, baking bread, culinary (KomeeB AK, J.KopacTymue CT »eao6HMe pacTeHHH b HameM πητβηηη, M., 1980, 256 c .; Food Technol. Abstr., 1974, N 93, p. 470) Their is added to kvass and other non-alcoholic and alcoholic beverages. Young leaves are good for salads, soups. Bees bring over 100 kg / ha of nectar from the blossoms.
Carum carvi kaip vaistinis augalas yra įtrauktas į daugelio šalių farmakopėjas. Vaisių antpilas (mokslinėje medicinoje) vartojamas skrandžio hipofunkcįjos (atonijos) atveju, esant meteorizmui (JleKapcTBeiiHbie npenapaTM, pa3pemeHHtie κ npHMeHemno b CCCP, M., 1979, 351 c.). Tibeto medicinoje - esant neurozėms, medžiagų apykaitos sutrikimams, intoksikacijoms, akių skausmams (AaKopaciynme nojie3HBie pacTemoi ψ/ιορω Μοηγολβοκοη HapoAHofi PecnySnHKH, JI., 1985, 235 c.). Kinų ir indų medicinoje - esant įvairioms skrandžio-žarnyno ligoms, chroniškam cholecistitui, kaip laktogeninė priemonė (lllpeTep A. H., HnMeHOB M. Γ. Pecypcu Ba>KHenmex neKapcTBeHHBix pacTeHHH coBeTCKoro Jjajibiiero BoeroKa // Pecypcu i(HKOpacTyuĮnx jieKapcTBeHHBix pacTeHHH CCCP, JI., 1968, c. 66-79; Chopra R. N., Nayr S. L., Chopra S. C., Glossary of Indian medicinai plants, New Delhi, 1956, 330 p.). Liaudies medicinoje įvairūs kmynų vaisių ekstraktai - diuretinė, atsikosėjimą gerinanti, apetitą žadinanti, virškinimą gerinanti priemonė, esant meteorizmui (3aBpa>KHOB B. H., KuTaeBa P. H., ΧΜβπβΒ K. Φ., JleKapcTBeHHEie pacTemia IĮeHTpajitHoro TepnoseMM, 3-e Η3Λ., BopoueJK, 1977, 447 c.). Esant bronchų astmai, ascitui, egzemai, kaip antihelmintinė priemonė (Pojijiob A. X. /ĮnKopacTymae pacreHHH KaBKa3a, hx pacnpocTpaHenne, CBO&TBa n npuMeHeitue, Th(Į>jihc, 1908, 599 c.; Caxo6nAHHHOB C. C. AnKopacTymne jieKapcTBenHbie pacTeHna CpeąHen A3hh, TauiKeHT, 1984, 199 c.). Ekstraktas (eterinis aliejus) eksperimento sąlygomis rodo antibakterinį aktyvumą (EoHjĮapeHKO A. C. h ąp., AuTiiMniipoGnaa aKTHBHOCTB HeK0T0pUX paCTeHHH // ΦΗΤΟΗΙίΗΛΜ B HapOJĮHOM XO3HHCTBe, Knen, 1964, c. 170179). Eterinis aliejus pasižymi antituberkulioziniu veikimu (MmųeHKOBa E. JI. h ąp., HeucTBue aHTH6H0THHecKnx BeiųecTB H3 bbiciuhx pacTenuu Ha MHKoSaKTepini // Μκκροδ. arypHaji, 1985, t. 47, N 1, c. 77-80).Carum carvi as a medicinal plant is included in the pharmacopoeias of many countries. Fruit infusion (in scientific medicine) is used in case of gastric hypofunction (atonia) in the presence of flatulence (JleKapcTBeiiHbie npenapaTM, pa3pemeHHtie κ npHMeHemno b CCCP, M., 1979, 351 c.). In Tibetan Medicine - Neuroses, metabolic disorders, intoxications, eye pains (AaKopaciynme nojie3HBie pacTemoi ψ / ιορω Μοηγολβοκοη HapoAHofi PecnySnHKH, JI. 1985, 235 c.). In Chinese and Indian Medicine - In Various Gastrointestinal Diseases, Chronic Cholecystitis, as a Lactogenic Remedy (lllpeTep AH, HnMeHOB M. Γ. Pecypcu Ba> KHenmex neKapcTBeHHBix pacTeHHH coBeTCKoro Jjajibiier. , pp. 66-79; Chopra RN, Nayr SL, Chopra SC, Glossary of Indian Medicinal Plants, New Delhi, 1956, p.330) In folk medicine, various cumin fruit extracts are diuretic, expectorant, appetite-inducing, and digestive. , in meteorism (3aBpa> KHOB BH, KuTaeBa PH, ΧΜβπβΒ K. Φ., JleKapcTBeHHEie pacTemia IĮeHTpajitHoro TepnoseMM, 3-e Η3Λ., BopoueJK, 1977, 447 c.). Pojijiob AX / InnKopacTymae pacreHHH KaBKa3a, hx pacnpocTpaHenne, CBO & TBa n npuMeHeitue, Th (In> jihc, 1908, 599 c.; Caxo6nAHHHOB CC AnKopacTymne theyKapcTBenHbieTeHeHeHeHeHeHeHeHeHeHeHeHeHeHeHeHe CeHeHeHeHeHeHeHeHeHeHeHeHeHeHiHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHC CCHHHHHHHH CC CCHKHKHHhhHHHHH CC 1984, 199 c.) The extract (essential oil) shows, under experimental conditions, antibacterial activity (EoHj ?apeHKO A. C. h? P., AuTiiMniipoGnaa aKTHBHOCTB HeK0T0pUX paCTeHHH // ΦΗΤΟΗΙίΗΛΜ B HAPOJIHOM XO3HHCTBe, 1966). 170179). Essential oil has antituberculosis activity (MmueHKOBa E.J.i.h., HeucTBue aHTH6H0THHecKnx BeiuecTB H3 bbiciuhx pacTenuu Ha MHKoSaKTepini // Μκκροδ. ArypHaji, 1985, vol.
Pastaruoju metu kmynai naudojami medicinoje kaip priemonė nuo meteorizmo, spazminių skrandžio bei žarnyno negalavimų esant virškinimo sutrikimams (Holtmann G. S., Haag B. et ai., 2003, Effects of a fixed combination of pipermint oil and caraway oil on symptoms and ąuality of life in patients suffering from functional dyspepsia. Phytomedicine 10 (suppl. 4): 56-57; Medisch A. G., Holtmann G. S. ei ai., 2004, Treatment of functional dyspepsia with a herbai preparation: a double blind, randomized, placebo controlled, multicenter trial. Digestion 69: 45-52). Kmynų ekstraktas ir eterinis aliejus naudojami skrandžio opų gydymui (Khayyal M. T., El-Ghazaly M. A. et ai., 2001. Antiulcerogenic effect of some gastrointestinally acting plant extracts and their combination. Arzneimittelforschung 51: 545-553).Kmynai pasižymi fungicidiniu veikimu - slopina Candida albicans - tai vienas labiausia paplitusių žmogaus patogeninių mikromicetų (Deeptha K. M. et ai., 2006. Dose dependent inhibitory effect of dietary caraway on 1,2-dimethylhydrazine induced colonic aberrant crypt foci and bacterial enzime activity in rats, Invest. New Drugs 24(6): 479-488).Cumin has recently been used in medicine as a remedy for flatulence, spasmodic gastrointestinal disorders and gastrointestinal disorders (Holtmann GS, Haag B. et al., 2003, Effects of a fixed combination of pipermint oil and caraway oil on the patient's life). suffering from functional dyspepsia Phytomedicine 10 (suppl. 4): 56-57; Medisch AG, Holtmann GS et al., 2004, Treatment of functional dyspepsia with a herbal preparation: a double blind, randomized, placebo controlled, multicenter trial. 69: 45-52). Caraway extract and essential oil are used for the treatment of gastric ulcers (Khayyal MT, El-Ghazaly MA et al., 2001. Antiulcerogenic effect of some gastrointestinal plant extracts and their combination. Arzneimittelforschung 51: 545-553). Caraway has fungicidal activity - suppresses Candida. albicans is one of the most common human pathogenic micromycetes (Deeptha KM et al., 2006. Dose dependent inhibitory effect of dietary caraway on 1,2-dimethylhydrazine-induced colonic aberrant crypt football and bacterial enzyme activity in rats, Invest. New Drugs 24 (6 ): 479-488).
Pateikiame detalesnę kmynų (Carum carvi) vaisių biologiškai aktyvių cheminių junginių charakteristiką.We present a more detailed description of the biologically active chemical compounds of Carum carvi fruit.
Kmynų vaisiuose eterinių aliejų randama nuo 2,6 iki 7,67 % (KapptieB M. O., ΦαρΜδκοχηΜΜ κβκοτορωχ 3$HpoMacjiHHHtix pacTeHHH φπορΒΐ TypKMeHHH, Auixa6a& 1973, 154 c.; CoSoJieBCKaa JI. A., TiopHHa E. B., TycaKOBa H. H. DtJmpoMacJimiHbie pacTeims jjajibiiero BocTOKa, Hoboch6hpck, 1972, c. 188; Karrer W. Konstitution und Vorkommen der organischen Pflanzenstoffe, Basei; Stuttgart, 1958, 1207 s). Eterinių aliejų sudėtyje randama procentais (%): karvono 41-60, limoneno 30, trans-dihidrokarvono, eis- dihidrokarvono, izodihidrokarvono, dihidrokarveolo, cis-karveolo, trans-karveolo, γ-terpineno, karvakrolo, izodihidrokarveolo, neodihidrokarveolo, neoizodihidrokarveolo, perilo alkoholio, dihidropinolo, acetaldehido, diacetilo, a-pineno, β-pineno, sabineno, mirceno, a-fenandreno, menteno, linaloolo, tricikleno, a-tuijono, β-tuijono, β-fencheno, kamieno, kareno, aterpineno, β-felandreno, β-kariofileno, β-kadineno, terpinoleno, timolo, trans-anetolo, kamforos, terpinenolo-4, petrozelino rūgšties (Embong M. B., Hudziger D. Molnar S., Essential oils irom species grown in Alberta: Caraway oil (Carum carvi) H Can J. Plant. Sci., 1977, vol. 57, N 2, p. 543-549; Ikeda R. M.et ai. The monoterpene hydrocarbon composition on some essential oils // J. Food, Sci., 1962, vol 27, N5, p. 455-458; Karrer W. Konstitution und Vorkommen der organischen Pflanzenstoffe, Basei, Stuttgart, 1958, 1207 s.; Masada Y. Analysis on essential oils by gas chromatography and mass-spektrometry, New York, 1976, 334 p.; Rothbacher H., Suten F. Ūber Hydroxylverbindungen dės Kūmmel - oils //Planta med., 1975, Bd. 28, H. 2, s. 112-123; Salveson A., Baerheim Svendsen A. Gas liąuid chromatographic separation and indication of the constituents of caraway seed oil // Planta med., 1976, Bd 30, H.l, p. 93-96; Schantz M., Huhtikengas A. Ūber die Bildung von Limonen und Carvon in Kūmmel - Carum carvi // Phytochemistry, 1971, vol 10, .N8, p. 1787-1793; Zderkiewicz T. Zawartošč oleiku w r6žnych fazach dojrzalosci owocow kminku di-i tetraploidalnego - Carum carvi L. //Actą agrobot., 1971, vol. 24, Nl, p. 121-122).Cumin essential oils are found in fruits from 2.6 to 7.67% (KapptieB MO, ΦαρΜδκοχηΜΜ κβκοτορωχ $ 3 HpoMacjiHHHtix pacTeHHH φπορΒΐ TypKMeHHH, Auixa6a & 1973, 154 c .; CoSoJieBCKaa JI. A., TiopHHa EC TycaKOBa HH DtJmpoMacJimiHbie pacTeims jjajibiiero BocTOKa, Hoboch6hpck, 1972, c. 188; Karrer W. Constitutions und Vorkommen der organischen Pflanzenstoffe (Basei; Stuttgart, 1958, 1207 s). Essential oils contain percentages (%): carvone 41-60, limonene 30, trans-dihydrocarvone, eis-dihydrocarvone, isodihydrocarvone, dihydrocarveol, cis-carveol, trans-carveol, γ-terpinene, carvacrol, isodihydrocarveol, neodihydrocarveol, neodihydrocarveol alcohol, dihydropinol, acetaldehyde, diacetyl, α-pinene, β-pinene, sabinene, mircene, α-phenandren, mentene, linalool, tricyclene, α-thione, β-thione, β-fenchen, strain, karen, aterpinene, β- felandren, β-caryophyllene, β-cadinene, terpinolene, thymol, trans-anethole, camphor, terpinenol-4, petroselic acid (Embong MB, Hudziger D. Molnar S., Essential oils and species grown in Alberta: Caraway oil (Carum carvi ) H Can J. Plant, Sci., 1977, vol. 57, N 2, pp. 543-549; Ikeda RMet et al., The monoterpene hydrocarbon composition on some essential oils // J. Food, Sci., 1962, vol. 27, N5, pp. 455-458; Karrer W. Constitution and Vorkommen der organischen Pflanzenstoffe, Basei, Stuttgart, 1958, 1207 pp .; Masada Y. Analysis on essential oils by gas chromatography and mass spectrometry, New York, 1976, 334 p .; Rothbacher H., Suten F. Uber Hydroxylverbindungen duh Kummel - Oils // Planta Med., 1975, Bd. 28, H. 2, s. 112-123; Salveson A., Baerheim Svendsen A. Gas Liquid Chromatographic Separation and Indication of the Components of Caraway Seed Oil // Planta Med., 1976, Bd 30, H.l, p. 93-96; Schantz, M., Huhtikeng, A. Uber die Bildung von Limonen und Carvon in Kummel - Carum carvi // Phytochemistry, 1971, vol 10, .N8, p. 1787-1793; Zderkiewicz T. Zawartošč oleiku w r6žnych fazach dojrzalosci owocow kminku di-i tetraploidalnego - Carum carvi L. // Act agrobot., 1971, vol. 24, Nl, p. 121-122).
Kmynų eteriniame aliejuje randami steroidai (organiniai junginiai, jų molekulės pagrindą sudaro ciklopentanoperhidrofenantreno žiedai): stigmasterinas, palmitatas ir stigmasterino stearatas (Kartnig Th., Scholz G. Ūber einige Lipoid-Inhaltstoffe aus den Frūchten vonSteroids (organic compounds based on cyclopentanoperhydrophenanthrene rings) found in cumin essential oil: stigmasterin, palmitate and stigmasterol stearate (Kartnig Th., Scholz G. Uber einige Lipoid-Inhaltstoffe aus den Früchten von
Pimpinella anisum und Carum carvi L. H Fette, Seifen, Anstrich mittel, 1969, Bd 71, H. 4, s.Pimpinella anisum und Carum carvi L. H Fette, Seifen, Anstrich mittel, 1969, Bd 71, H. 4, s.
276-280).276-280).
Fenolkarboninės rūgštys ir jų dariniai: 4-P-D-gliukopiranoziloksibenzoinė rūgštis (Dirks V.,Phenolic carbonic acids and their derivatives: 4-P-D-glucopyranosyloxybenzoic acid (Dirks V.,
Hermann K., 4-(p-Glukopyranosyloxy)-benzoic acid, a characteristic phenolic constituent of the Apiaceae // Phytochemistry, 1984, vol. 23, N 8, p. 1811-1812).Hermann K., 4- (p-Glucopyranosyloxy) benzoic acid, a characteristic phenolic constituent of the Apiaceae // Phytochemistry, 1984, vol. 23, N 8, p. 1811-1812).
Kumarinai (heterocikliniai deguonies junginiai, augaluose esantys glikozidų pavidalo kumarinai vadinami laktonais) - 0,02-0,48 % (BajiyųKaa A. Γ., rycbKOBa H. A., CoaepiKaHue KyMapuHOB b ch6hpckhx npencTaBHTenax ceM. 3ohtiihhhx // PacT. pecypcbi, 1972, t. 8, ββιπ. 4, c. 547-554; KapptueB M. O. <&apMaKOXHMHS ΗβκοτορΒίχ 3(įmpoMacjiHHHi>ix pacTenun φπορΒΐ TypKMeHHH, Auixa6ąn, 1973,154 c.): umbeliferonas, skopolitinas, herniarinas.Coumarins (Heterocyclic oxygen compounds, plant-derived glycosidic coumarins called lactones) - 0.02-0.48% (BajiyųKaa A. Γ., RycbKOBa HA, CoaepiKaHue KyMapuHOB b ch6hpckhx npencTaBHTenax ceM. .8, ββιπ. 4, c. 547-554; KapptueB MO <& apMaKOXHMHS ΗβκοτορΒίχ 3 (inmpoMacjiHHHi> ix pacTenun φπορΒΐ TypKMeHHH, Auixa6ąn, 1973,154 c.): Umbelinone.
Flavonoidai (įvairios spalvos augaliniai pigmentai, priklauso glikozidams) - 0,98-1,24 % (Kunzemann J., Hermann K. Isolierung und Identifizierung der Flavon(ol)-0-glykoside in Kūmmel (Carum carvi L.), Fenchel (Foeniculum vulgare Mill,), Anis (Pimpinella anisum L.) und Koriander (Coriandrum sativum L.) und von Flavon-C-glykosiden im Anis, Z. Lebensmitteluntersuch. und Forsch., 1977, Bol 164, H. 3, s. 194-200): kvercetino 3gliukoronidas, izokvercizinas, rutinas, kvercetino 3-0-kofeoilgliukozidas, kempferolio 3glikozidas.Flavonoids (various colored plant pigments belonging to the glycosides) - 0.98-1.24% (Kunzemann J., Hermann K. Isolation and Identification of Flavon (ol) -O-glycoside in Kumel (Carum carvi L.), Fenchel ( Foeniculum vulgare Mill,), Anis (Pimpinella anisum L.) and Coriander (Coriandrum sativum L.) and von Flavon-C-glycosiden im Anis, Z. Lebensmitteluntersuch and Forsch., 1977, Bol 164, H. 3, p. 194-200): Quercetin 3-Glucosonide, Isocvercizine, Rutin, Quercetin 3-0-Caffeoyl Glucoside, Kempferol 3-Glycoside.
Riebalai (vienas svarbiausių ląstelės komponentų, glicerino ir riebalų rūgščių esteriai) - 18,421,18 %. Jų sudėtyje (%): angliavandeniliai 0,2; trigliceridai 66; laisvosios riebalų rūgštys 5,1 (petrozelino, palmitino, stearino, linoleno,oleino). (3apaflcKa» E. H., EopucioK K). Γ. HccJienoBaHHe χαίρΗΒΐχ khcjiot πλολοβ τμηηη - Carum carvi L. h araca Pimpinella anisum L. /HeKOTopue Bonpocw įapMaunn, KneB, 1956, c. 185-189; CTenaHeHKO Γ. A., TycaKOBa C. ĮĮ., YMapoB A. Y., Jlunuųbi ceMaii Carum carvi h Foeniculum vulgare // Xhmm npnpoą. coeflHH., 1980, N 6, c. 827-828; Hondelmann W. Das Vorkommen einer ungewohlingen Fettsaure, der Petroselinsaure, in der Familie der Doldengewachse als Ausganspunkt fur die Entwicklung neuer Olfruchte H Landbauforsch. Volkenrode, 1985, Jd 35, H. 4/, s. 185-190; Kleiman R., Spencer C. F., Search for new industrial oils: Umbelliferae seed oils rich in petroselinic acid H J. Americ. Oil Chem. Soc, 1982, vol. 59, N 1, p. 29-38).Fat (one of the most important components of the cell, glycerol and fatty acid esters) - 18,421,18%. It contains (%): hydrocarbons 0,2; triglycerides 66; free fatty acids 5,1 (petrozelin, palmitic, stearic, linolenic, oleic). (3apaflcKa »E. H., EopucioK K). Γ. HccJienoBaHHe χαίρΗΒΐχ khcjiot πλολοβ τμηηη - Carum carvi L. h araca Pimpinella anisum L. / HeKOTopue Bonpocw inapMaunn, KneB, 1956, c. 185-189; CTenaHeHKO Γ. A., TycaKOBa C. IN., YMapoB A. Y., Jlunuaibi ceMaii Carum carvi h Foeniculum vulgare // Xhmm npnpoą. coeflHH., 1980, N 6, c. 827-828; Hondelmann W. Das Vorkommen einer ungewohlingen Fettsaure, Petroselinsaure, in Familie der Doldengewachse als Ausganspunkt fur die Entwicklung neuer Olfruchte H Landbauforsch. Volkenrode, 1985, Jd 35, H. 4 /, s. 185-190; Kleiman R., Spencer C. F., Search for New Industrial Oils: Umbelliferae Seed Oils Rich in Petroselinic Acid H J. Americ. Oil Chem. Soc, 1982, vol. 59, N 1, p. 29-38).
Kompoziciją gaunama tokiu būdu: sausus Carum carvi (paprastojo kmyno) vaisius, kaip vaistinę žaliavą turinčius ne daugiau kaip 12 % drėgmės, ne mažiau kaip 5-6 % eterinių aliejų ir ne daugiau kaip 8-9 % mineralinių medžiagų, o pelenų, netirpstančių 10 % druskos rūgštyje, ne daugiau kaip 1,5-2,0 %, susmulkina ir ekstrahuoja 60-96 % etilo alkoholiu, geriau 96 % etilo alkoholiu, per 24-72 vai. 18-20 °C temperatūroje kratant, gaunama fitocheminių junginių tinktūra.The composition is obtained as follows: dry Carum carvi (caraway) fruit, containing as a medicinal raw material no more than 12% moisture, not less than 5-6% essential oils and not more than 8-9% minerals, and ash insoluble 10 in hydrochloric acid, not more than 1.5-2.0%, crushed and extracted with 60-96% ethyl alcohol, preferably 96% ethyl alcohol, in 24-72 hours. Shaking at 18-20 ° C gives a tincture of phytochemicals.
Taip paruošta kompoziciją naudojama mastopatijąi gydyti, kur kompozicijos terapinė dozė/dienai ligoniui skiriama 7,5-12,5 ml arba 150-250 lašų vartojimui per OS po 30-50 lašų 5 kartus per dieną ne mažiau kaip 30 min. prieš valgį, geriau vienodais laiko intervalais. Kompozicijos nešikliu yra vartojama sacharozę, kurios vienkartinę dozę sudaro 5-7 g sacharozės.The composition so prepared is used to treat mastopathy, wherein the therapeutic dose / day of the composition is administered to the patient at 7.5 to 12.5 ml or 150 to 250 drops via the OS at 30 to 50 drops 5 times daily for at least 30 minutes. before meals, preferably at equal intervals. The carrier of the composition is sucrose in a single dose of 5-7 g of sucrose.
Ekstrakto aktyvumui įvertinti naudotos nelinijinės žiurkės ir pelės, o taip pat linijinės pelės DBA/2, BDF, C57B1 ir BALB/C. Eksperimentiniams gyvūnams buvo įskiepijami sarkomos (S-45), sarkomos (S-180) ir pieno liaukos adenokarcinomos (Ca 755) augliai. Tiriamasis ekstraktas eksperimentiniams gyvūnams buvo suleidžiamas į pilvo ertmę nuo kelių iki keliolikos ml/kg svorio. Ekstraktai žiurkėms buvo suleidžiami nuo eksperimentinio auglio ląstelių transplantacijos praėjus 3-5 paroms, pelėms - praėjus 1-2 paroms. Ekstraktai buvo leidžiami iki 5 kartų. Ekstrakto aktyvumo įvertinimo trukmė -10 parų.Non-linear rats and mice as well as linear mice DBA / 2, BDF, C57B1 and BALB / C were used to evaluate the activity of the extract. The experimental animals were grafted with tumors of sarcoma (S-45), sarcoma (S-180), and adenocarcinoma of the mammary gland (Ca 755). The test extract was injected into the abdominal cavity of experimental animals from a few to a dozen ml / kg. Extracts were injected in rats 3-5 days after experimental tumor cell transplantation and in mice 1-2 days. Extracts were allowed up to 5 times. The evaluation of the activity of the extract is -10 days.
Ekstrakto aktyvumas buvo vertinamas auglio ląstelių augimo slopinimu, išreiškiamu procentais (%), palyginus su kontroliniu variantu, o taip pat eksperimentinio gyvūno kūno ir blužnies masės pokyčiais (%). Gauti teigiami rezultatai. Kmyno vaisių ekstraktas (tinktūra) pieno liaukų adenokarcinomos (Ca 755) ląstelių augimą slopino 90 %.The activity of the extract was evaluated as a percentage (%) of tumor cell growth inhibition relative to the control, as well as changes in body and spleen weight (%) of the experimental animal. Positive results were obtained. Cumin fruit extract (tincture) inhibited the growth of mammary gland adenocarcinoma (Ca 755) cells by 90%.
Nustatyta terapinė dozė (TD) mg/kg. Ji yra 30-90 mg/kg per parą. Tuomet smulkaus svorio (50 kg) ligonei - 1500-2500 mg/50 kg per parą sausos kmyno vaisių masės, arba šį kiekį transformavus į 60 % etilo alkoholio ekstraktą (kai kmyno vaisių masės ir alkoholio santykis 1:5) turėsime (1,5 arba 2,5 g x 5) 7,5-12,5 ml alkoholio ekstrakto. Tai paros (tikriau, dienos norma). Ekstraktas naudotinas lašais (1 ml = 20 lašų). Taigi dienos norma (dozė) - 150-250 ekstrakto lašų. Ši dozė rekomenduojama per os vartoti 5 kartus per dieną po 30-50 ekstrakto lašų vienam kartui, mažiausiai pusę valandos prieš valgį. Tinkamiausias ekstrakto (tinktūros) nešėjas - sacharozę (cukrus), 5-7 g sacharozės, į kurią lašinama 30 arba 50 tinktūros lašų ir taip paruošiama vienkartinė dozė mastopatijai gydyti. Ši procedūra vienodais laiko intervalais per dieną atliekama 5 kartus.The therapeutic dose (TD) was determined in mg / kg. It is 30-90 mg / kg / day. Then, for a patient with a low weight (50 kg), 1500-2500 mg / 50 kg / day dry cumin fruit mass, or if this amount is transformed into 60% ethyl alcohol extract (caraway fruit weight to alcohol ratio 1: 5) we will have (1.5 or 2.5 gx 5) 7.5 to 12.5 ml alcohol extract. It's daily (or rather, the daily rate). The extract should be used in drops (1 ml = 20 drops). Thus, the daily dose (dose) is 150-250 drops of extract. This dose is recommended to be taken orally 5 times a day after 30-50 drops of extract once, at least half an hour before meals. The most suitable carrier for the extract (tincture) is sucrose (sugar), 5-7 g of sucrose, which is given in 30 or 50 drops of tincture to prepare a single dose for mastopathy. This procedure is performed 5 times at equal time intervals per day.
Kmyno vaisių ekstrakto (tinktūros) efektyvumo vertinimas buvo atliktas ir kitu būdu vertinant citotoksinį kompozicijos poveikį piktybinių ląstelių kultūroje iri vitro. Tuo tikslu naudotas 3-(4,5-dimetiltiazol-2-il)-2,5-difeniltetrazolio bromidas (MTT). Tai vienas dažniausiai naudojamų būdų ląstelių proliferacijai ir citotoksiškumui vertinti (Mosmann T. 1983. Rapid calorimetric assay for cellular grovvth and survival: Application to proliferation and cytotoxicity assay. J. Immunol. Methods 65, 55-63). Tetrazolio druskos sudaro didelę heterociklinių organinių junginių grupę, kurios po redukcijos visada virsta spalvotais, dažnai netirpiais junginiais. Geltonos spalvos MTT redukuoja metaboliškai aktyvios ląstelės, veikiant mitochondrijų fermentams dehidrogenazėms. Šio proceso išdava - vandenyje netirpus, bet tirpstantis etanolyje, izopropanolyje bei rūgštiniame izopropanolyje, spalvotas formazanas. Vandenyje netirpus formazanas gali būti tirpinamas ir mineraliniame aliejuje, tačiau, šiuo atveju farmazano nuosėdos turi būti inkubuojamos iki 24 vai. 37 °C temperatūroje, kai dimetilsulfokside (DMSO) formazano nuosėdos ištirpsta nedelsiant (Kasagai S. N. et ai., 1990. A simple in vitro cytotoxicity tęst using the MTT (3-(4,5)dimethylyhiazol-2-yl)-2,5 diphenyl tetrazolium bromide) colometric assay; anglysis of angenol toxicity on dental pulp cells (RPC - C2A), Japan J. Pharmacol 52: 95-100). Gautas tirpalas vertinamas spektrometriškai 500-600 mm bangos ilgyje. Šis metodas visuotinai pripažintas, tinkamas priešvėžinių junginių tyrimams, svarbus klinikoje (Hatok J. E., Babusikova T., et ak, 2009. In vitro assays for the evaluation of drug resistance in tumor cells. Clin. Exp, Med. 9: 1-7).An evaluation of the efficacy of cumin fruit extract (tincture) was also performed to evaluate the cytotoxic effects of the composition in malignant cell culture and in vitro. For this purpose, 3- (4,5-dimethylthiazol-2-yl) -2,5-diphenyltetrazolium bromide (MTT) was used. It is one of the most commonly used methods for assessing cell proliferation and cytotoxicity (Mosmann T. 1983. Rapid calorimetric assay for cellular groove and survival: Application to proliferation and cytotoxicity assay. J. Immunol. Methods 65, 55-63). Tetrazole salts form a large group of heterocyclic organic compounds which, after reduction, always turn into colored, often insoluble, compounds. Yellow MTT is reduced by metabolically active cells through the action of mitochondrial enzymes dehydrogenases. The result of this process is water-insoluble but soluble in ethanol, isopropanol and acid isopropanol, colored formazan. Water-insoluble formazan can also be solubilized in mineral oil, but in this case the pharman sediment should be incubated for up to 24 hours. At 37 ° C, when dimethyl sulfoxide (DMSO) formazan precipitate dissolves immediately (Kasagai SN et al., 1990. A simple in vitro cytotoxicity is continued using the MTT (3- (4,5) dimethylyhiazol-2-yl) -2,5) diphenyl tetrazolium bromide) colometric assay; angular toxicity of dental pulp cells (RPC-C2A), Japan J. Pharmacol 52: 95-100). The solution obtained is evaluated spectrometrically at a wavelength of 500-600 mm. This method is generally recognized as being suitable for anticancer compound assays in the clinic (Hatok JE, Babusikova T., et al., 2009. In vitro assays for the evaluation of drug resistance in tumor cells. Clin. Exp. Med. 9: 1-7). .
Tyrimai atlikti tokia darbo tvarka.The investigations were carried out in the following order.
Kmynų ekstrakto paruošimas.Preparation of cumin extract.
Kmynų sėklos mechaniškai susmulkinamos (sumalamos). Susmulkinta masė ekstrahuojama 96 % etilo alkoholiu 24 vai. kambario temperatūroje kratant. Naudotas kmynų sėklų ir etilo alkoholio santykis 1:10 (1 g kmynų sėklų 10 ml 96 % etilo alkoholio).The caraway seeds are mechanically crushed (ground). The pulp is extracted with 96% ethyl alcohol for 24 hours. at room temperature by shaking. A 1:10 ratio of cumin seeds to ethyl alcohol (1 g of cumin seeds in 10 ml of 96% ethyl alcohol) was used.
Naudotos ląstelės bei jų auginimo sąlygos.Used cells and growing conditions.
Darbe buvo vertintas spiritinio kmynų ekstrakto poveikis krūtų vėžio - MCF7, plaučių vėžio A549 bei neuroblastomos - N2A linijų ląstelėms. Ląstelių linijos gautos iš ATCC (American Type Culture Collection). Ląstelės augintos Iscove modifikuotoje Dulbeco terpėje (IMDM), praturtintoje 10 % fetalinių veršelių serumu ir antibiotikais - penicilinu (100 V V) ir streptomicinu (100ųg/ml). Ląstelės persėjamos 2-3 kartus per savaitę, jų monosluoksnį disperguojant EDTA-tripsino (4:1) mišiniu. Ląstelės auginamos 37 °C temperatūroje, aplinkoje esant 5 % CO2 ir 95 % drėgmei.The effect of spirit cumin extract on breast cancer cells MCF7, lung cancer A549 and neuroblastoma N2A cells was evaluated. Cell lines were obtained from ATCC (American Type Culture Collection). Cells were grown in Iscove's modified Dulbec's medium (IMDM) enriched in 10% fetal calf serum and antibiotics penicillin (100 U) and streptomycin (100 µg / ml). Cells are seeded 2-3 times per week by dispersing their monolayer with EDTA-trypsin (4: 1). Cells were grown at 37 ° C, 5% CO 2 and 95% humidity.
Kmynų poveikio ląstelių gyvybingumui tyrimas.Study of the effect of cumin on cell viability.
Dieną prieš poveikį, tiriamos ląstelės išsėjamos maždaug 200 ląstelių/ml suspensijos tankiu į 96 duobučių polistirolinę plokštę. Po 24 vai. ląstelėms pradėjus daugintis, augimo terpė pakeičiama nauja terpe, kurioje yra skirtingos koncentracijos kmynų ekstraktai. Lygiagrečiai buvo tiriamas ir ekstragenįo- etilo alkoholio bei pavienio kmynų ekstrakto poveikis tiriamų ląstelių proliferacijai ir gyvybingumui. Abiem atvejais poveikio trukmė - 24 vai.The day before exposure, test cells are plated at a density of approximately 200 cells / ml in a 96-well polystyrene plate. After 24 or. as cells multiply, the growth medium is replaced by a new medium containing different concentrations of cumin extracts. In parallel, the effects of extragen-ethyl alcohol and single cumin extract on the proliferation and viability of the cells were investigated. In both cases, the exposure duration is 24 hours.
Ląstelių proliferacinio aktyvumo įvertinimas.Evaluation of cell proliferative activity.
Tiriamų ląstelių proliferacija buvo vertinama naudojant MTT reagentą. Metodas paremtas gyvų ląstelių mitochondrijų fermentų gebėjimu tirpų geltonos spalvos MTT [3-(4,5dimetiltiazoI-2-il)-2,5-difeniltetrazolio bromidą] redukuoti iki violetinės spalvos netirpius kristalus formuojančio formazano. Gyvų ląstelių skaičius yra tiesiogiai proporcingas susidariusio produkto - formazano kiekiui, kuris įvertinamas spekrtofotometriškai 570 nm bangos ilgyje, gautus netirpius kristalus ištirpinus etanolyje. Proliferacijos įvertinimui naudojamas 0,2 mg/ml MTT tirpalas fosfatiniame buferyje, kurio 50 μΐ/cm2 pilama ant ląstelių monosluoksnio prieš tai pašalinus auginimo terpę. Inkubuojama 1 vai., susidariusios nuosėdos tirpinamos etanoliu, kurio pilama 100 μΐ/cm2. Optinis tankis matuojamas spekrtofotometriškai 570 nm bangos ilgyje.Proliferation of test cells was evaluated using MTT reagent. The method is based on the ability of live cell mitochondrial enzymes to reduce soluble yellow MTT [3- (4,5-dimethylthiazol-2-yl) -2,5-diphenyltetrazolium bromide] to purple-insoluble crystalline formazan. The number of viable cells is directly proportional to the amount of product formed, formazan, which is estimated spectrophotometrically at 570 nm by dissolving the insoluble crystals in ethanol. For the proliferation assessment, a 0.2 mg / ml MTT solution in phosphate buffer, 50 μΐ / cm 2, is added to the cell monolayer after the culture medium is removed. Incubate for one hour and dissolve the precipitate in ethanol at 100 μΐ / cm 2 . The optical density is measured spectrophotometrically at 570 nm.
Išradimo apibendrintam aiškinimui toliau pateikiami pavyzdžiai.The following examples are provided to illustrate the invention.
pavyzdys. Carum carvi alkoholinio ekstrakto (tinktūros) priešvėžinis aktyvumas (auglio ląstelių kultūros: Ca755, S-45, S-180)example. Anticancer activity of alcoholic extract (tincture) of Carum carvi (tumor cell cultures: Ca755, S-45, S-180)
pavyzdys. Carum carvi alkoholinio ekstrakto (tinktūros) priešvėžinis aktyvumas (auglio ląstelių linijos: MCF7, N2A, A549)example. Anticancer activity of alcoholic extract (tincture) of Carum carvi (tumor cell lines: MCF7, N2A, A549)
2-ojo pavyzdžio rezultatai gauti naudojant kitokią tyrimo metodiką, nei 1-ojo pavyzdžio atveju. Jie patvirtina 1-ojo pavyzdžio duomenis - Carum carvi tinktūra stabdo pieno liaukos adenokarcinomos vystymąsi (ląstelių dauginimąsi), ir tas stabdymas yra statistiškai patikimas.The results of Example 2 were obtained using a different assay methodology than that of Example 1. They confirm the data of Example 1 - Carum carvi tincture inhibits the development of adenocarcinoma (cell proliferation) of the mammary gland, and this inhibition is statistically reliable.
Carum carvi vaisių tinktūra, atsižvelgiant įjoję esantį netoksinį fitocheminių junginių rinkinį ir jų gydomąjį efektą gali būti vertinama kaip nereceptinis fitoterapinis vaistinis preparatas. Jis tinka pieno liaukų adenokarcinomos profilaktikai ir gydymui. Taip pat gali būti naudojama pooperaciniu laikotarpiu bei chemoterapijos būdo taikymo atveju. Kmyno vaisių fitocheminiai junginiai tinktūros ar kitu pavidalu (milteliai, granulės) perspektyvūs derinyje su šiuolaikiniais vaistiniais preparatais, naudojamais vėžio įvairių formų chemoterapijoje, o taip pat derinyje su kitų vaistinių augalų produkuojamais junginiais, pasižyminčiais priešvėžinėmis savybėmis.Carum carvi fruit tincture, given its non-toxic set of phytochemicals and their therapeutic effect, can be considered as a non-prescription phytotherapeutic drug. It is suitable for the prevention and treatment of adenocarcinoma of the mammary glands. It can also be used in the postoperative period and in the case of chemotherapy. Cumin fruit phytochemicals in tincture or other forms (powders, granules) are promising in combination with modern medicinal products used in various forms of cancer chemotherapy, as well as in combination with other medicinal herbs with anticancer properties.
Claims (6)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| LT2010027A LT5701B (en) | 2010-03-29 | 2010-03-29 | Phytochemical composition, method of preparation and use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| LT2010027A LT5701B (en) | 2010-03-29 | 2010-03-29 | Phytochemical composition, method of preparation and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| LT2010027A LT2010027A (en) | 2010-10-25 |
| LT5701B true LT5701B (en) | 2010-12-27 |
Family
ID=42984341
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LT2010027A LT5701B (en) | 2010-03-29 | 2010-03-29 | Phytochemical composition, method of preparation and use thereof |
Country Status (1)
| Country | Link |
|---|---|
| LT (1) | LT5701B (en) |
Citations (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2034561C1 (en) | 1992-07-10 | 1995-05-10 | Тихоокеанский институт биоорганической химии Дальневосточного отделения РАН | Method for producing of remedy for mastopathy treating |
| RU2066168C1 (en) | 1994-05-23 | 1996-09-10 | Александр Иванович Суханов | Method for treating the cases of fibrotic and cystic mastopathy |
| WO1996037210A2 (en) | 1995-05-26 | 1996-11-28 | Ropapharm B.V. I.O. | Pharmaceutical compositions, based on etheric oils obtained from plants for use in the human and veterinary medical field |
| CN1385202A (en) | 2002-05-14 | 2002-12-18 | 邹明廉 | Medicine for treating mastosis and preparation process thereof |
| CN1493349A (en) | 2003-09-16 | 2004-05-05 | 江苏苏中药业股份有限公司 | A pharmaceutical composition for treating cyclomastopathy, and its preparation method |
| CN1657069A (en) | 2004-04-29 | 2005-08-24 | 倪艳龙 | Traditional Chinese medicine for treating mastopathy |
| CN1695694A (en) | 2005-05-11 | 2005-11-16 | 陈志强 | Chinese traditional medicine for treating breast disease and preparing technique |
| CN1757297A (en) | 2005-11-07 | 2006-04-12 | 米永红 | Keeping in good health type tea containing multiflower knotweed and tetraphyllous ginseng |
| CN1759899A (en) | 2005-10-31 | 2006-04-19 | 徐守健 | Hygienical bra of Chinese traditional medicine |
| CN1861183A (en) | 2006-04-04 | 2006-11-15 | 聂秀英 | Traditional Chinese medicine capsule for treating mammary gland diseases |
| CN1883552A (en) | 2006-05-20 | 2006-12-27 | 姜川 | A Chinese medicine for treating mastopathy and method for preparing same |
| CN1895441A (en) | 2006-06-12 | 2007-01-17 | 翁春杨 | Medicament for treating mastopathy |
| CN101129527A (en) | 2007-08-23 | 2008-02-27 | 王培凤 | Medicament for treating glandula mammaria disease |
| CN101214298A (en) | 2007-12-29 | 2008-07-09 | 石家庄开发区捷达技术贸易公司 | Externally-applied pharmaceutical composition for treating mazopathy |
| CN101485862A (en) | 2009-02-27 | 2009-07-22 | 程裕厚 | Chinese medicament preparation for treating mastopathy |
-
2010
- 2010-03-29 LT LT2010027A patent/LT5701B/en not_active IP Right Cessation
Patent Citations (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2034561C1 (en) | 1992-07-10 | 1995-05-10 | Тихоокеанский институт биоорганической химии Дальневосточного отделения РАН | Method for producing of remedy for mastopathy treating |
| RU2066168C1 (en) | 1994-05-23 | 1996-09-10 | Александр Иванович Суханов | Method for treating the cases of fibrotic and cystic mastopathy |
| WO1996037210A2 (en) | 1995-05-26 | 1996-11-28 | Ropapharm B.V. I.O. | Pharmaceutical compositions, based on etheric oils obtained from plants for use in the human and veterinary medical field |
| CN1385202A (en) | 2002-05-14 | 2002-12-18 | 邹明廉 | Medicine for treating mastosis and preparation process thereof |
| CN1493349A (en) | 2003-09-16 | 2004-05-05 | 江苏苏中药业股份有限公司 | A pharmaceutical composition for treating cyclomastopathy, and its preparation method |
| CN1657069A (en) | 2004-04-29 | 2005-08-24 | 倪艳龙 | Traditional Chinese medicine for treating mastopathy |
| CN1695694A (en) | 2005-05-11 | 2005-11-16 | 陈志强 | Chinese traditional medicine for treating breast disease and preparing technique |
| CN1759899A (en) | 2005-10-31 | 2006-04-19 | 徐守健 | Hygienical bra of Chinese traditional medicine |
| CN1757297A (en) | 2005-11-07 | 2006-04-12 | 米永红 | Keeping in good health type tea containing multiflower knotweed and tetraphyllous ginseng |
| CN1861183A (en) | 2006-04-04 | 2006-11-15 | 聂秀英 | Traditional Chinese medicine capsule for treating mammary gland diseases |
| CN1883552A (en) | 2006-05-20 | 2006-12-27 | 姜川 | A Chinese medicine for treating mastopathy and method for preparing same |
| CN1895441A (en) | 2006-06-12 | 2007-01-17 | 翁春杨 | Medicament for treating mastopathy |
| CN101129527A (en) | 2007-08-23 | 2008-02-27 | 王培凤 | Medicament for treating glandula mammaria disease |
| CN101214298A (en) | 2007-12-29 | 2008-07-09 | 石家庄开发区捷达技术贸易公司 | Externally-applied pharmaceutical composition for treating mazopathy |
| CN101485862A (en) | 2009-02-27 | 2009-07-22 | 程裕厚 | Chinese medicament preparation for treating mastopathy |
Also Published As
| Publication number | Publication date |
|---|---|
| LT2010027A (en) | 2010-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gupta et al. | PHCOG MAG.: Plant review Withania somnifera (Ashwagandha): A review | |
| Fazal et al. | Physicochemical, phytochemical evaluation and DPPH-scavenging antioxidant potential in medicinal plants used for herbal formulation in Pakistan | |
| KR20160014707A (en) | Compositions and methods for joint health | |
| Agrawal et al. | Herbal remedies for treatment of hypertension | |
| Arora et al. | A review on phytochemical and pharmacological potential of genus Chelidonium | |
| KR102876481B1 (en) | Herbal composition | |
| Ho et al. | Traditional practice, bioactivities and commercialization potential of Elephantopus scaber Linn | |
| US7618663B2 (en) | Anti-arthritic herbal composition and method thereof | |
| CN103479963A (en) | Traditional Chinese medicine capsules for treating rheumatoid arthritis and preparation method thereof | |
| Nagarkar et al. | Comparative evaluation of anti-inflammatory potential of medicinally important plants | |
| KR100834850B1 (en) | Combination herbal composition with anti-allergic rhinitis, anti-atopic dermatitis or anti-chronic asthma effect | |
| Raut et al. | Pharmacognosti c and pharmacological aspects on Tabernaemontana divaricata plant | |
| Kumar et al. | Phytochemical analysis, in-vitro screening for antimicrobial and anthelmintic activity of combined hydroalcoholic seed extracts of four selected folklore indian medicinal plants | |
| CN102188671B (en) | Chinese medicinal preparation for treating chronic cholecystitis | |
| Borquaye et al. | Anti-inflammatory, antioxidant and total phenolic content of the ethanolic extracts of Celtis africana Burm. f | |
| Hurinanthan | Anti-HIV activity of selected South African medicinal plants | |
| Teja et al. | Phytochemical and In vitro Anti-inflammatory Activity on Abrus precatorius | |
| Kalariya et al. | Pharmacological potential of Citrus medica: a review. | |
| Rose et al. | Invitro antibacterial activity of methanolic root extract of Tinospora cordifolia (Willd) | |
| KR101423875B1 (en) | A composition comprising the complex extract for preventing or treating stroke and degenerative brain disease | |
| Patel | Preparation and Standardization of some herbal Antidiabetic drugs in Polyherbal Formulation | |
| Aboobecker et al. | To study analgesic, hypoglycemic and hepatoprotective activity of Moringa olefera leaf extract in Albino wistar rats | |
| LT5701B (en) | Phytochemical composition, method of preparation and use thereof | |
| Sultana et al. | Antihyperglycemic and antihyperlipidemic effects of Stephania japonica (thunb.) Miers. Tenril in alloxan induced diabetic mice | |
| Dafar et al. | A Review on Phytochemical and Pharmacological Study of Herbal Medicinal Plant: Abrus precatorious |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM9A | Lapsed patents |
Effective date: 20130329 |